Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.
This publication reports real-world outcomes for ciltacabtagene autoleucel (cilta‑cel), an anti‑BCMA CAR‑T therapy...
Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights.
- Post category:Hematologic Cancers
- Reading time:2 mins read
This publication reviews the emerging role of circulating tumor cells (CTCs) as a liquid biopsy tool in multiple myeloma...
HCT Pre-App program: a telemedicine-based prehabilitation for allogeneic hematopoietic cell transplant candidates.
- Post category:Hematologic Cancers
- Reading time:2 mins read
This study reports on a structured frailty and prehabilitation program for allogeneic HCT candidates at a single institu...
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).
- Post category:Hematologic Cancers
- Reading time:2 mins read
This study evaluated why only some patients with t(11;14)(CCND1;IGH) multiple myeloma benefit durably from venetoclax....
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.
- Post category:Hematologic Cancers
- Reading time:2 mins read
This publication reports a comparative effectiveness analysis of linvoseltamab, a BCMA×CD3 bispecific antibody, versus...
Management of hematological toxicities after BCMA-directed CAR-T cell therapy.
- Post category:Hematologic Cancers
- Reading time:2 mins read
This study evaluated whether the CAR-HEMATOTOX (CAR-HT) score can guide supportive care in multiple myeloma patients rec...